TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›BCAB›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

BioAtla, Inc. (BCAB) financials

Income statement

BioAtla, Inc. (BCAB) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue——$300K————
Operating income-$28.3M-$30.1M-$96.4M-$108M-$130M-$73.9M-$59.3M
Operating margin——-32146.7%————
Net income-$29.9M-$35.9M-$95.4M-$106M-$123M-$69.8M-$59.6M
Net margin——-31800.7%————
EPS (diluted)—-$3.19-$2.76-$2.74-$2.58-$1.44-$1.01

Cash flow

BioAtla, Inc. (BCAB) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$9.64M-$36.3M-$62.2M-$90.4M-$104M-$71.9M-$48.2M

Balance sheet

BioAtla, Inc. (BCAB) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$3.70M$239M$245M$216M$111M$49.0M$7.12M
Total assets—$245M$254M$226M$120M$52.4M$13.8M
Total liabilities—$35.0M$43.6M$45.4M$49.0M$38.2M$50.0M
Shareholders' equity-$56.0M$210M$211M$180M$70.7M$14.3M-$36.2M
Retained earnings—-$90.9M-$186M-$293M-$416M-$486M-$546M
Shares (wtd avg diluted)—32.2M34.6M38.9M47.8M48.6M58.8M

Every figure is extracted from BioAtla, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does BCAB pay a dividend?
BioAtla, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full BCAB analysis — verdict, score & filings →Is BCAB a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.